Marinus Pharmaceuticals (Marinus Pharmaceuticals) Debt-to-Equity : 4.40 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Marinus Pharmaceuticals Debt-to-Equity?

Marinus Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.33 Mil. Marinus Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $61.42 Mil. Marinus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $16.77 Mil. Marinus Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 4.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Marinus Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

MRNS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.21 Max: 4.4
Current: 4.4

During the past 12 years, the highest Debt-to-Equity Ratio of Marinus Pharmaceuticals was 4.40. The lowest was 0.01. And the median was 0.21.

MRNS's Debt-to-Equity is ranked worse than
98.04% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs MRNS: 4.40

Marinus Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Marinus Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals Debt-to-Equity Chart

Marinus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.02

0.81

0.62

4.40

Marinus Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.62	0.88	1.29	1.36	4.40

Competitive Comparison of Marinus Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Marinus Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marinus Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinus Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Marinus Pharmaceuticals's Debt-to-Equity falls into.

Marinus Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Marinus Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.325	+	61.423)	/	16.765
	=	4.40

Marinus Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.325	+	61.423)	/	16.765
	=	4.40

Marinus Pharmaceuticals (NAS:MRNS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Marinus Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinus Pharmaceuticals (Marinus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (NAS:MRNS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MRNS:Mexico 61Y:Germany

Address

100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.marinuspharma.com

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Executives

Christina Shafer	officer: Chief Commercial Officer	5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Steven Pfanstiel	officer: CFO	5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Joseph Hulihan	officer: Chief Medical Officer	5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087
Martha E Manning	officer: VP, Gen. Counsel & Corp. Sec.	700 PENNSYLVANIA DR, EXTON PA 19341
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Marvin Johnson	director	C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Elan Ezickson	director	AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Charles Austin	director	5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Christine Berni Silverstein	director	C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Santiago Arroyo	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Sara Nochur	director	295 WOODCLIFF RD, NEWTON MA 02461
Nicole Vitullo	director, 10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Edward F Smith	officer: Chief Financial Officer	C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104